ArticleJournal of thoracic disease2019
Effect of second primary cancer on the prognosis of patients with non-small cell lung cancer.
Article in Journal of thoracic disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Diagnostic value of surveillanceEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Incidence Patterns and Prognostic Impact of Lung-Involving Multiple Primary Cancers: A 10-Year Hospital-Based Cohort Study.Thoracic cancer · 2026Article
- Article
- Surgical selection and regional lymph node dissection for stage I second primary lung cancer patients following surgery for stage I first primary lung cancer.Frontiers in oncology · 2023Article
- Survival Analysis in Patients with Lung Cancer and Subsequent Primary Cancer: A Nationwide Cancer Registry Study.Journal of clinical medicine · 2022Article
- Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers.Journal of clinical medicine · 2022Article
- Prevalence and Clinical Significance of Incidental FocalMolecular imaging and radionuclide therapy · 2022Article
- Clinical Value of SurveillanceCancers · 2022Article
- Better Prognosis and Survival in Esophageal Cancer Survivors After Comorbid Second Primary Malignancies: A SEER Database-Based Study.Frontiers in surgery · 2022Article
- Risks and cancer associations of metachronous and synchronous multiple primary cancers: a 25-year retrospective study.BMC cancer · 2021Article
- Role of chemotherapy for survival in patients with second primary non-small cell lung cancer.Thoracic cancer · 2021Article
- Second Primary Malignancies in Patients with Pancreatic Neuroendocrine Neoplasms: A Population-Based Study on Occurrence, Risk Factors, and Prognosis.Journal of oncology · 2021Article
- Prognostic study for survival outcome following the treatment of second primary lung cancer in patients with previously resected non-small cell lung cancer.Thoracic cancer · 2020Article
- Prognostic outcome after second primary lung cancer in patients with previously treated lung cancer by radiotherapy.Journal of thoracic disease · 2020Article
- Risk of second primary malignancy in adults with pulmonary high-grade neuroendocrine carcinoma (HGNEC).BMC cancer · 2020Article
- Survival of Patients with First and Metachronous Second Primary Breast Cancer or Lung Cancer Malignancy: Comparisons Using the SEER Database.Advances in therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSecond primary cancer (SPC) is not a rare event for patients with non-small cell lung cancer (NSCLC), especially for those who survive for a longer period of time. This study was aimed to explore the effects of SPC on the survival of NSLCL patients.
methodsA total of 241,805 patients with primary NSCLC were identified between 2004 and 2014 from the Surveillance, Epidemiology, and End Results (SEER) database. The incidence of SPC and its effect on the overall survival (OS) and lung cancer-specific survival (LCSS) was explored and analyzed using Cox regression model with SPC being treated as a time-dependent covariate.
resultsThe incidence of SPCs after the diagnosis of NSCLC was 6.4%, with the second primary lung cancer being the most common one (45.1%). About half of the SPCs (50.7%) occurred during the first year after the diagnosis of NSCLC. It seemed that patients who developed SPC late in the follow-up period tended to have poor prognosis. Multivariable analysis with Cox regression showed that the occurrence of SPC was a poor prognostic factor for patients with NSCLC [hazard ratio (HR), 1.298; 95% confidence interval (CI), 1.270-1.326; P=0.000], and it increased the risk of LCSS (versus no SPC, HR, 1.094; 95% CI, 1.066-1.123; P=0.000).
conclusionsThe occurrence of SPC after the diagnosis of NSCLC was not a rare event, and it indicated a poorer prognosis compared with patients without it. During the follow-up, attention should be paid to the screening of SPC especially the second primary lung cancer, and a rational surveillance policy should be formed and implemented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.